Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Abbott Laboratories (ABT), AbbVie Inc (ABBV): Why Investors Should Care About Hepatitis C

Page 1 of 2

Hepatitis C, caused by the hepatitis C virus (HCV), is an infectious disease affecting the liver. An estimated 130 million-200 million people worldwide are infected with hepatitis C, and more than 350,000 people die every year from hepatitis C-related liver diseases.


HCV is the most common chronic blood-borne infection in the United States and the leading cause of liver transplants, according to the Centers for Disease Control and Prevention. There are at least six different subtypes of the hepatitis C virus, and each responds differently to treatment. On June 20, the U.S. Food and Drug Administration (FDA) approved a test that identifies the genotype of hepatitis C virus (HCV) that a patient is carrying. By using a sample of an infected patient’s blood plasma or serum, the Abbott RealTime HCV Genotype II can differentiate genotypes 1, 1a, 1b, 2, 3, 4, and 5. By knowing the type of HCV a person is infected with, more effective treatment can be given as different HCV genotypes respond differently to available drug therapies.

FIX Hedge Funds Are Crazy About Abbott Laboratories (NYSE:ABT)

The Abbott RealTime HCV Genotype II test is manufactured by Abbott Molecular, owned by Abbott Laboratories (NYSE:ABT). Abbott has a strong commitment with a long history to hepatitis and has developed the first commercial tests for detection of hepatitis B and tests for hepatitis A. After the separation of AbbVie Inc (NYSE:ABBV), Abbott Laboratories (NYSE:ABT) focuses more on the diagnostics segment. Fueled by strong revenue growth from point-of-care and core-lab units, the diagnostic segment reported a 4.4% increase in revenue in the last quarter.

The worldwide hepatitis C market is forecast to grow from $3.8 billion in 2011 to $14.5 billion in 2020, boosted by increase in diagnosis rates following an increase in screening, as well as the introduction of more effective and tolerable pipeline agents.


While careful screening is essential for the treatment to determine the most appropriate approach for the patient, traditional combination antiviral therapy with interferon and ribavirin still faces some challenges. More effective and better-tolerated drugs are needed. AbbVie Inc (NYSE:ABBV) and Gilead Sciences, Inc. (NASDAQ:GILD) are racing to launch a new generation of all-oral hepatitis C drugs, whereas Gilead’s new drug can cure 95% of patients after eight weeks of therapy and AbbVie Inc (NYSE:ABBV)’s treatment delivered a slightly lower cure rate of 90% in a Phase II trial. Both drugs provide faster cures with less side effects, and the first drug to the market should quickly penetrate the estimated $20 billion market. For Gilead, the new drug is estimated to have annual sales of $6.03 billion by 2016, according to the analysts’ estimates compiled by Bloomberg, whereas analysts are projecting $10.62 billion of total revenue for fiscal 2013. As for AbbVie Inc (NYSE:ABBV), the new hepatitis C drugs could generate annual sales of $3 billion, as estimated by Morningstar analyst Damien Conover. Analysts currently are projecting total annual revenue of $18.48 billion for fiscal 2013 for AbbVie Inc (NYSE:ABBV).

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!